Leerink Partners analyst Jonathan Chang maintained a Hold rating on Rubius Therapeutics (NASDAQ:RUBY) on Monday, setting a price target of $20, which is approximately 21.73% above the present share price of $16.43.
Chang expects Rubius Therapeutics to post earnings per share (EPS) of -$0.50 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Rubius Therapeutics, with an average price target of $23.33.
The analysts price targets range from a high of $40 to a low of $10.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$39.72 million. The company's market cap is $1.33 billion.
According to TipRanks.com, Leerink Partners analyst Jonathan Chang is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 32.7% and a 53.85% success rate.
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan and is headquartered in Cambridge, MA.